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Abstract The 68 kDa Src substrate associated during mitosis is
an RNA binding protein with Src homology 2 and 3 domain
binding sites. A role for Src associated in mitosis 68 as an
adaptor protein in signaling transduction has been proposed in
different systems such as T-cell receptors. In the present work,
we have sought to assess the possible role of Src associated in
mitosis 68 in insulin receptor signaling. We performed in vivo
studies in HTC-IR cells and in vitro studies using recombinant
Src associated in mitosis 68, purified insulin receptor and fusion
proteins containing either the N-terminal or the C-terminal Src
homology 2 domain of p85 phosphatidylinositol-3-kinase. We
have found that Src associated in mitosis 68 is a substrate of the
insulin receptor both in vivo and in vitro. Moreover, tyrosine-
phosphorylated Src associated in mitosis 68 was found to
associate with p85 phosphatidylinositol-3-kinase in response to
insulin, as assessed by co-immunoprecipitation studies. There-
fore, Src associated in mitosis 68 may be part of the signaling
complexes of insulin receptor along with p85. In vitro studies
demonstrate that Src associated in mitosis 68 associates with the
Src homology 2 domains of p85 after tyrosine phosphorylation
by the activated insulin receptor. Moreover, tyr-phosphorylated
Src associated in mitosis 68 binds with a higher affinity to the
N-terminal Src homology 2 domain of p85 compared to the
C-terminal Src homology 2 domain of p85, suggesting a
preferential association of Src associated in mitosis 68 with the
N-terminal Src homology 2 domain of p85. This association may
be important for the link of the signaling with RNA metabolism.
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1. Introduction
Insulin binding to the extracellular domain of insulin recep-
tors (IRs) on the surface of the cell induces a signal trans-
duction cascade, which then propagates inside the cell to me-
diate the uptake and storage of energy and to control gene
expression and proliferation [1^3]. IRs are heterotetrameric
transmembrane glycoproteins (two K- and two L-subunits)
[4]. The K-subunit is completely extracellular and mediates
insulin binding, whereas the L-subunit has an intracellular
domain containing a tyrosine-speci¢c kinase similar to that of
the proto-oncogene product Src [5]. When insulin binds to the
K-subunit, intrinsic tyrosine kinase of the L-subunit is acti-
vated, autophosphorylates [6] and tyrosine phosphorylates
cellular proteins [7]. IR substrate 1 (IRS-1) is a major cellular
substrate for the IR [8]. Multiple tyrosine phosphorylations of
IRS-1 in speci¢c motifs renders IRS-1 to interact with various
Src homology (SH) 2 containing proteins including the p85
regulatory subunit of phosphatidylinositol-3-kinase (PI3K)
[9,10]. The IR itself, via its C-terminal Tyr-1322-Thr-His-
Met motif following tyrosine phosphorylation, is also capable
of interacting with a SH2 domain of a PI3K p85 subunit
[11,12]. PI3K is a heterodimer enzyme that consists of a
p110 catalytic subunit [13] and a p85 regulatory subunit
[14]. A P85 subunit contains two SH2 domains and one
SH3 domain that interact with phosphorylated tyrosines in
speci¢c motifs [15] and proline-rich domains, respectively
[16]. PI3K activity has been implicated in insulin-stimulated
glucose transport and glycogen synthesis [17^19]. Following
insulin stimulation, PI3K forms various signaling complexes
with downstream IR proteins [20]. They include the IR, IRS-1
and p60^p70 kDa phosphoproteins. One of these proteins has
been previously identi¢ed as the p62 GTPase activating pro-
tein (GAP)-associated protein [21,22]. A protein ¢rst thought
to be p62 GAP-associated protein [23] is Src associated with
mitosis (Sam) 68 which is known to be tyrosine-phospho-
rylated in mitotic cells and to form a complex with Src by
interactions with both SH2 and SH3 domains of Src [24,25].
Sam68 is able to bind RNA because it contains a KH domain
and a region similar to a RGG box [26,27] that are predictive
for RNA binding proteins. Sam68 has been shown to bind to
single-stranded nucleic acid [28]. A splice variant within the
KH domain of Sam68 has decreased RNA binding properties
and can antagonize cell cycle progression [29]. Because Sam68
is tyrosine-phosphorylated in mitotic cells and has proline-rich
domains, Sam68 interacts with signaling molecules both
through SH2 and SH3 domains [30,31]. Besides, tyrosine
phosphorylation of Sam68 negatively regulates its nucleic
acid binding properties [28,32]. These data suggested that
Sam68 might have a role in signaling events. In fact, Sam68
participates in the signal transduction pathway downstream of
the T-cell receptor in lymphocytes [33,34]. Our hypothesis was
that Sam68 might be part of the IR signaling.
2. Materials and methods
2.1. Antibodies and recombinant proteins
Recombinant Sam68, monoclonal antibodies anti-Sam68 (K-Sam68)
and anti-IR (K-IR) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Antiserum to the p85K regulatory subunit of
PI3K (K-p85) and glutathione S-transferas (GST) fusion proteins con-
taining either the N- or C-SH2 domain were from Upstate Biotech-
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nology (Lake Placid, NY, USA). Monoclonal antibodies to phospho-
tyrosine (K-PY) were purchased from Transduction Laboratories
(Lexington, KY, USA).
2.2. Cells and preparation of soluble cell lysates
Rat HTC hepatoma cells overexpressing human IR (HTC-IR) were
kindly provided by Dr. Ira D. Gold¢ne (UCSF, San Francisco, CA,
USA). Cells were prepared and maintained in Dulbecco’s modi¢ed
Eagle’s medium as previously described [21]. For experiments, cells
were grown in 100 mm dishes to 90% con£uency and serum-starved
for 24 h. They were treated for di¡erent times at 37‡C with 100 nM
insulin or di¡erent insulin concentrations for 5 min and solubilized for
30 min at 4‡C in lysis bu¡er containing 20 mM Tris, pH 8, 1% non-
idet P-40, 137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 1 mM dithio-
threitol (DTT), 10% glycerol, 1 mM phenylmethylsulfonyl £uoride
(PMSF) and 0.4 mM sodium orthovanadate [21]. After centrifugation,
the soluble cell lysates were used for the study. The protein concen-
tration was determined by a kit from Bio-Rad (Richmond, CA, USA),
using bovine serum albumin as standard.
2.3. Immunoprecipitation
Soluble cell lysates (2 mg protein) were ¢rst pre-cleared with 50 Wl
protein A-Sepharose for 2 h at 4‡C and incubated with appropriate
antibodies for 2 h at 4‡C. 50 Wl of protein A-Sepharose was then
added and the incubation was further proceeded for 1 h at 4‡C.
The immunoprecipitates were washed three times with lysis bu¡er.
50 Wl of SDS-stop bu¡er containing 100 mM DTT was added to
immunoprecipitates and boiled for 5 min. These were then analyzed
by Western blotting. Samples were resolved by SDS-PAGE and elec-
trophoretically transferred onto nitrocellulose membranes. The mem-
branes were blocked with Tris-bu¡ered saline-0.05% Tween 20
(TBST) containing 5% non-fat dry milk for 1 h, washed in TBST
and further incubated with secondary antibodies linked to horseradish
peroxidase. Bound horseradish peroxidase was visualized by a high
sensitive chemiluminescence system (SuperSignal from Pierce, Rock-
fold, IL, USA).
2.4. IR puri¢cation
IRs were semi-puri¢ed by wheat germ agglutinin (WGA) chroma-
tography from HTC-IR cells as previously described [12]. Cells were
solubilized in 1% Triton X-100 containing 50 mM HEPES, pH 7.6,
1 mM PMSF, 1 mM sodium orthovanadate and 0.1 mg/ml aprotinin.
Next, the solubilized cells were centrifuged at 50 000Ug for 1 h. The
soluble extract was puri¢ed on a 2 ml column containing WGA
coupled to agarose and eluted with 0.3 M N-acetyl-L-glucosamine
as previously described [12]. Semi-puri¢ed (WGA) material was fur-
ther puri¢ed by immunoa⁄nity with anti-IR antibodies coupled to
protein A-Sepharose. IRs were immunoprecipitated as previously de-
scribed [35]. IR immunoprecipitates were employed for the in vitro
tyrosine phosphorylation reaction.
2.5. In vitro phosphorylation of Sam68
A⁄nity-puri¢ed IR from HTC-IR, immobilized with protein A-Se-
pharose, was incubated with or without 100 nM insulin for 1 h in 50
mM HEPES (pH 7.6), 150 mM NaCl, 10 mM MgCl2, 2 mM MnCl2,
0.1% Triton X-100, 1 mg/ml bacitracin and 1 mM PMSF. ATP (for 10
WM ¢nal concentration) was then added and incubation continued for
1 h. Next, 100 fmol recombinant Sam68 (Santa Cruz Biotechnology)
was added to the reaction mixture and further incubated for 1 h. The
mixture was centrifuged and supernatant containing Sam68 was em-
ployed for in vitro interaction with GST fusion proteins.
2.6. A⁄nity precipitation with GST fusion proteins
Reaction mixture containing in vitro phosphorylated or basal re-
combinant Sam68 (diluted 10-fold with reaction bu¡er minus Mg/Mn
and ATP) was incubated for 2 h at 4‡C with the GST-(PI3K) p85 N-
or C-SH2 domain fusion protein (2 Wg) conjugated with glutathione
agarose (GST-p85 (N) and GST-p85 (C), respectively). After centri-
fugation, a⁄nity precipitates were washed three times with lysis reac-
tion mixture (minus Mg/Mn and ATP) and boiled in 50 Wl SDS-stop
bu¡er. Samples were then analyzed by Western blotting as described
above.
3. Results
3.1. Sam68 is tyrosine-phosphorylated in HTC-IR cells upon
insulin stimulation and associates with p85 PI3K
Using HTC-IR cells, we studied the in vivo tyrosine phos-
phorylation of Sam68 by insulin stimulation. Sam68 is phos-
phorylated in the presence of serum (not shown), but after 24
h of serum starving, the phosphorylation level is almost un-
detectable. As shown in the immunoprecipitate with K-Sam68
(Fig. 1, upper panel), Sam68 was slightly tyrosine-phosphoryl-
ated in basal conditions. Nevertheless, when cells were incu-
bated with 100 nM insulin, the tyrosine phosphorylation level
of Sam68 was transiently increased. The time-course of this
e¡ect of insulin showed that the Sam68 phosphorylation level
was maximal at 5 min and slowly decreased after 10 min,
although the level of phosphorylation after 20 min incubation
was still signi¢cantly increased. Scanning of the bands and
analysis with the PCBAS2.0 program showed that phospho-
rylation levels at 10 and 20 min were 76 þ 15% and 47 þ 9%
(means þ S.D.) of that observed at 5 min. To further demon-
strate the physiological importance and the speci¢city of this
e¡ect of insulin on tyrosine phosphorylation of Sam68, we
performed dose-response experiments (Fig. 1, lower panel)
at the 5 min time-point. This e¡ect of insulin was dependent
on the concentration, it was signi¢cantly observed at 1 nM
(27 þ 4% of maximum) and was maximal at 100 nM insulin.
At 10 nM insulin, phosphorylation of Sam68 reached 48 þ 5%
of the maximum.
The immunoprecipitate with K-p85 also showed p60^70 ty-
rosine-phosphorylated proteins after 5 min insulin stimulation
(Fig. 2A) as previously reported [12,21]. To check whether
Sam68 was one of these tyrosine-phosphorylated proteins,
we probed the samples from Fig. 2A with K-Sam68 after
stripping the membrane (Fig. 2C). Some amount of Sam68
seems to be associated with p85 in basal conditions (6 þ 2% of
the immunoprecipitable Sam68), but this association was in-
creased about four times after 5 min of insulin stimulation (up
to 26 þ 5%). Therefore, Sam68 is one of the proteins associ-
Fig. 1. Time-course and dose-response of insulin-induced tyrosine
phosphorylation of Sam68. Cells were incubated with 100 nM insu-
lin for di¡erent times (upper panel) or for 5 min at di¡erent concen-
trations (lower panel) and solubilized. Cell lysates were then immu-
noprecipitated with K-Sam68 and analyzed by Western blotting with
K-PY. One experiment representative of three for each panel is
shown.
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ated with p85 after insulin stimulation. To con¢rm the in vivo
association of Sam68 with p85, we used the opposite ap-
proach (Fig. 2B). Thus, we look for the co-immunoprecipita-
tion of p85 with K-Sam68. Similar results to those of K-Sam68
were obtained. Thus, some amount of p85 is associated with
Sam68 (4 þ 1% of the immunoprecipitable p85), but this asso-
ciation is signi¢cantly increased (about four times) upon in-
sulin stimulation (up to 21 þ 6%) (Fig. 2B). Sam68 recognizes
two bands of 62 and 68 kDa as described in other cell lines
[34] and both are tyrosine-phosphorylated after insulin stim-
ulation (Figs. 1 and 2A). To quantify the percentage of
Sam68, we calculated the average of the two bands.
3.2. Sam68 is tyrosine-phosphorylated by the activated IR in
vitro and associates with the SH2 domains of p85
A⁄nity-puri¢ed IR immobilized with protein A-Sepharose
was incubated with or without 100 nM insulin for 1 h and
further incubated with 10 WM ATP in the presence of divalent
cations. Recombinant Sam68 (100 fmol) was then added and
the incubation continued for 1 h. The reaction mixture (super-
natant containing Sam68) was then incubated with immobi-
lized GST-p85 fusion proteins and the precipitates were ana-
lyzed by Western blotting with K-PY (Fig. 3A). Analysis of
the total reaction mixture revealed that Sam68 was tyrosine-
phosphorylated by the activated IR. Both GST-p85 (N) and
GST-p85 (C) precipitated Sam68. Besides, GST-p85 (N) more
e¡ectively precipitated Sam68 compared to GST-p85 (C). To
con¢rm this di¡erential a⁄nities, we repeated the experiment
with di¡erent amounts of fusion proteins (Fig. 3B and C).
GST-p85 (N) at 0.02 Wg (500 fmol) interacted signi¢cantly
with phosphorylated Sam68 (100 fmol), but it did not interact
with GST-p85 (C) until 0.1 Wg (2.5 pmol) of this fusion pro-
tein was employed. Maximal binding of Sam68 was obtained
with 1 Wg (25 pmol) of GST-p85 (N) (Fig. 3B) whereas 5 Wg
(125 pmol) of GST-p85 (C) was needed to bind the same
amount of Sam68 (Fig. 3C).
4. Discussion
The present study indicates that Sam68, the Src-associated
protein in mitosis, is tyrosine-phosphorylated by the IR and is
part of the signaling complexes elicited by insulin stimulation.
Previous work has shown that Sam68 is a substrate of the
Fig. 2. Insulin-induced tyrosine phosphorylation of Sam68 and its
association with p85 in vivo. Cells were incubated for 5 min with
100 nM insulin and solubilized. Cell lysates were then immunopreci-
pitated with K-Sam68 and K-p85 and analyzed by Western blotting
with K-PY (A). The same immunoprecipitates were then analyzed
by Western blotting with K-p85 (B) and K-Sam68 (C). One represen-
tative experiment of four is shown.
Fig. 3. Insulin-induced tyrosine phosphorylation of Sam68 in vitro
and association with the SH2 domains of p85. (A) A⁄nity-puri¢ed
IR (bound to protein A-Sepharose) was incubated with recombinant
Sam68 (100 fmol) in a tyrosine phosphorylation reaction with or
without insulin, in the presence of 10 WM ATP and divalent cations
as described in Section 2. Samples were then centrifuged and super-
natant containing Sam68 was taken and diluted in reaction bu¡er
(minus divalent cations and ATP), incubated for 1 h with the GST-
p85-SH2 (N or C) conjugated with glutathione agarose and then
precipitated. Samples were then denatured and analyzed by Western
blotting with K-PY. One experiment representative of ¢ve is shown.
(B) Di¡erential a⁄nities of phosphorylated Sam68 with GST-p85
(N) and GST-p85 (C) fusion proteins. Sam68 was tyrosine-phos-
phorylated in vitro as described in A. The reaction mixture contain-
ing phosphorylated Sam68 was then diluted in reaction bu¡er (mi-
nus divalent cations and ATP) and incubated for 2 h with di¡erent
amounts of either GST-p85 (N) or GST-p85 (C) fusion proteins
conjugated to glutathione agarose and precipitated. These precipi-
tates were then washed and analyzed by Western blotting with K-
PY. One representative experiment of three is shown.
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tyrosine kinase c-Src and the threonine kinase Cdc2 during
mitosis [24,25,36]. We have studied tyrosine phosphorylation
of Sam68 in resting cells, which were serum-starved for 24 h.
The time-course of Sam68 tyrosine phosphorylation showed a
rapid and transient e¡ect after insulin stimulation, even at a
nanomolar concentration, suggesting a direct action of the IR
kinase. We cannot exclude the participation of other kinases
in this e¡ect of insulin in vivo, however. Nevertheless, in vitro
studies with puri¢ed IR and recombinant Sam68 have dem-
onstrated that Sam68 may be a direct substrate of IR. Even
though we have employed a cell line overexpressing IRs, the
dose-response e¡ect of insulin suggests that this e¡ect may be
also relevant in a more physiological model with a normal
number of IRs. The e¡ect of insulin at a nanomolar concen-
tration also demonstrates the speci¢city of the action through
IRs rather than IGF-1 receptors.
Sam68 is able to bind RNA and contains a KH domain and
a region similar to a RGG box [26,27], characteristic for a
distinct family of RNA binding proteins [37]. Sam68 is there-
fore a putative regulator of the RNA metabolism and it could
give means for a rapid pathway to regulate protein expression
by modifying the mRNA stability and/or mRNA translation
[38,39]. Besides, p68 may serve to target the mRNA in the
cytoplasm [40] to deliver speci¢c proteins to speci¢c struc-
tures, i.e. the cytoskeletal proteins that usually contain SH3
domains, and therefore, to provide means to mediate the in-
teractions. We propose that p68 Sam may be a substrate for
the IR and by tyrosine phosphorylation of p68, the metabo-
lism of RNA might be regulated as it has been suggested in
other systems [28,32]. This mechanism could allow the cell to
respond much faster than protein expression from the novo
transcription, when stimulated by insulin.
Sam68 is known to associate with the SH2 and SH3 do-
mains of Src and other signaling molecules such as Grb2,
PLC-Q-1 or p85K with di¡erent a⁄nities [24,35,30^32].
Sam68 has therefore been envisioned as an adaptor protein
in signaling systems such as the T-cell receptor [33,34]. In the
present study, we have found an in vivo association of Sam68
with p85K even in basal conditions, but this association is
increased upon insulin stimulation about four times, probably
due to tyrosine phosphorylation. In vitro studies seem to sup-
port this hypothesis, since tyrosine phosphorylation of Sam68
by IR increases the association with the SH2 domains of p85.
Moreover, the in vitro association studies with phosphoryl-
ated Sam68 and p85 (N) or p85 (C) demonstrated that the
binding a⁄nity of Sam68-p85 (N) was higher than that of
Sam68-p85 (C). These data strongly suggest that Sam68 is
part of the signaling complexes of the IR and that it may
function as an adaptor molecule to link the IR signaling cas-
cade with the regulation of ARN metabolism.
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